Stage- and CA125–related survival in patients with epithelial ovarian cancer treated at a cancer center
Corresponding Author
R.E. BOARD
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Address correspondence and reprint requests to: Dr Ruth Board, BSc, MBChB, Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester M20 4BX, UK. Email: [email protected]Search for more papers by this authorC.T.P.H. BRUIJNS
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorA.E. PRONK
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorW.D.J. RYDER
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorP.M. WILKINSON
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorR. WELCH
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorJ.H. SHANKS
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorG. CONNOLLY
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorR.J. SLADE
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorK. REYNOLDS
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorH.C. KITCHENER
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorG.C. JAYSON
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorCorresponding Author
R.E. BOARD
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Address correspondence and reprint requests to: Dr Ruth Board, BSc, MBChB, Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester M20 4BX, UK. Email: [email protected]Search for more papers by this authorC.T.P.H. BRUIJNS
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorA.E. PRONK
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorW.D.J. RYDER
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorP.M. WILKINSON
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorR. WELCH
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorJ.H. SHANKS
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorG. CONNOLLY
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorR.J. SLADE
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorK. REYNOLDS
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorH.C. KITCHENER
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorG.C. JAYSON
*Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester, United Kingdom; †Maastricht University, Maastricht, The Netherlands; Departments of ‡Medical Statistics, §Clinical Oncology, ‖Pathology, and ¶Gynaecological Oncology Surgery, Christie Hospital, Manchester, United Kingdom; and #Department of Gynaecological Oncology, St. Mary's Hospital, Manchester, United Kingdom
Search for more papers by this authorAbstract
Abstract. Board RE, Bruijns CTPH, Pronk AE, Ryder WDJ, Wilkinson PM, Welch R, Shanks JH, Connolly G, Slade RJ, Reynolds K, Kitchener HC, Jayson GC. Stage- and CA125–related survival in patients with epithelial ovarian cancer treated at a cancer center. Int J Gynecol Cancer 2006;16(Suppl. 1):18–24.
Current accepted prognostic indicators in ovarian cancer include performance status, surgical (FIGO) staging, and residual disease after operation. Here we present data from a prospective analysis of patients with ovarian cancer treated at the Christie Hospital. We confirm the independent prognostic effects of FIGO staging, performance status, and residual disease in our group of patients and furthermore show that CA125 levels at presentation to the oncology service are of independent prognostic significance (P= 0.02). We present survival data and show that the 3-year, cancer-specific survival for stage I disease is 90%. We postulate that this good survival may in part be due to the use of computed tomography scanning at presentation to allow accurate staging. Further clinical trials are needed to test whether combinations of surgical, histologic, biochemical, and radiologic parameters can be used to identify a population with such a good prognosis that adjuvant therapy is not required.
References
- 1 Colombo N, Guthrie D, Chiari S et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003; 95: 125–32.
- 2 Trimbos JB, Parmar M, Vergote I et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant Chemotherapy in Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 2003; 95: 105–12.
- 3
Hankinson SE,
Coldotz GA,
Hunter DJ.
A prospective study of reproductive factors and risk of epithelial ovarian cancer.
Cancer
1995; 76: 284–90.
10.1002/1097-0142(19950715)76:2<284::AID-CNCR2820760219>3.0.CO;2-5 CAS PubMed Web of Science® Google Scholar
- 4 Allen DG, Heintz AP, Touw FW. A meta-analysis of residual disease and survival in stage III and IV carcinoma of the ovary. Eur J Gynaecol Oncol 1995; 16: 349–56.
- 5 Vergote I, De Brabanter J, Fyles A et al. Prognostic importance of degree of differentiation and cyst rupture in stage 1 invasive epithelial ovarian carcinoma. Lancet 2001; 357: 176–82.
- 6 Rustin GJ, Nelstrop AE, McClean P et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA125. J Clin Oncol 1996; 14: 1545–51.
- 7 Rustin GJ, Nelstrop AE, Tuxen MK, Lambert HE. Defining progression of ovarian carcinoma during follow up according to serum CA125: a North Thames Ovary Group Study. Ann Oncol 1996; 7: 361–4.
- 8 Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81.
- 9 Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1–39.
- 10
Cox DR.
Regression models and life-tables (with discussion).
J R Stat Soc
1972; 34: 187–220.
10.1111/j.2517-6161.1972.tb00899.x Google Scholar
- 11 Grambsch PM, Therneau TM, Fleming TR. Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics 1995; 51: 1469–82.
- 12 Ho CM, Huang YJ, Chen TC et al. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 2004; 94: 197–203.
- 13 Sevelda P, Schemper M, Spona J. CA 125 as an independent prognostic factor for survival in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1989; 161: 1213–6.
- 14 Makar AP, Kristensen GB, Kaern J, Bormer OP, Abeler VM, Trope CG. Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis. Obstet Gynecol 1992; 79: 1002–10.
- 15 Nagele F, Petru E, Medl M, Kainz C, Graf AH, Sevelda P. Preoperative CA 125: an independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995; 86: 259–64.
- 16 Trimbos JB, Vergote I, Bolis G et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 2003; 95: 113–25.
- 17 Kolomainen DF, A’Hern R, Coxon FY et al. Can patients with relapsed, previously untreated, stage I epithelial ovarian cancer be successfully treated with salvage therapy? J Clin Oncol 2003; 21: 3113–8.
- 18 Zanetta G, Rota S, Chiari S et al. The accuracy of staging: an important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis. Ann Oncol 1998; 9: 1097–101.
